ADICET BIO INC(NASDAQ:ACET) stock News

ACET Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Chartmill - Mentions: NAK BTM AEHR APVO ...

Tuesday's session: gap up and gap down stocks

21 hours ago - By: Adicet Bio, Inc.

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

10 days ago - By: Benzinga

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

10 days ago - By: Adicet Bio, Inc.

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

10 days ago - By: Adicet Bio, Inc.

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

16 days ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

17 days ago - By: Zacks Investment Research

Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know

a month ago - By: Adicet Bio, Inc.

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Benzinga - Mentions: CLDX ALC BLRX TLPH ...

12 Health Care Stocks Moving In Tuesday's After-Market Session

2 months ago - By: Zacks Investment Research

Adicet Bio (ACET) Upgraded to Buy: Here's Why

2 months ago - By: Yahoo Finance - Mentions: MXCT

MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio

2 months ago - By: The Motley Fool

Adicet Bio (ACET) Q2 Loss Widens 3%

2 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

2 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

3 months ago - By: Adicet Bio, Inc.

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

5 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

5 months ago - By: Zacks Investment Research

Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know

5 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

6 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

6 months ago - By: Adicet Bio, Inc.

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

6 months ago - By: Adicet Bio, Inc.

Adicet Bio Appoints Michael Grissinger to the Board of Directors

7 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

7 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

8 months ago - By: Adicet Bio, Inc.

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

8 months ago - By: Adicet Bio, Inc.

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

8 months ago - By: Stocktwits - Mentions: SHPH LPTX NXTC KURA

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

8 months ago - By: Adicet Bio, Inc.

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

9 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

9 months ago - By: Adicet Bio, Inc.

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

9 months ago - By: Adicet Bio, Inc.

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

10 months ago - By: Adicet Bio, Inc.

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

10 months ago - By: Adicet Bio, Inc.

ADICET BIO INC (ACET) Stock News

ACET Latest News, Press Relases and Analysis

Tuesday's session: gap up and gap down stocks

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2

Adicet Bio, Inc. Announces $80 Million Registered Direct Offering

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know

Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12 Health Care Stocks Moving In Tuesday's After-Market Session

Adicet Bio (ACET) Upgraded to Buy: Here's Why

MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio

Adicet Bio (ACET) Q2 Loss Widens 3%

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference

Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

Adicet Bio Appoints Michael Grissinger to the Board of Directors

Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma